Medical - Devices
Compare Stocks
5 / 10Stock Comparison
PEN vs ISRG vs SYK vs MDT vs ZBH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Devices
PEN vs ISRG vs SYK vs MDT vs ZBH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $12.67B | $159.85B | $109.33B | $97.62B | $16.12B |
| Revenue (TTM) | $1.45B | $10.58B | $25.12B | $35.48B | $8.41B |
| Net Income (TTM) | $171M | $2.98B | $3.25B | $4.61B | $761M |
| Gross Margin | 67.4% | 66.3% | 63.5% | 61.9% | 70.0% |
| Operating Margin | 12.9% | 30.5% | 22.4% | 17.9% | 15.6% |
| Forward P/E | 65.8x | 43.3x | 19.1x | 13.8x | 9.7x |
| Total Debt | $220M | $303M | $14.86B | $28.52B | $7.52B |
| Cash & Equiv. | $187M | $3.37B | $4.01B | $2.22B | $592M |
PEN vs ISRG vs SYK vs MDT vs ZBH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Penumbra, Inc. (PEN) | 100 | 186.9 | +86.9% |
| Intuitive Surgical,… (ISRG) | 100 | 232.8 | +132.8% |
| Stryker Corporation (SYK) | 100 | 145.8 | +45.8% |
| Medtronic plc (MDT) | 100 | 77.2 | -22.8% |
| Zimmer Biomet Holdi… (ZBH) | 100 | 67.2 | -32.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PEN vs ISRG vs SYK vs MDT vs ZBH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PEN has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 17.5%, EPS growth 11.6%, 3Y rev CAGR 18.3%
- Lower volatility, beta 0.23, Low D/E 15.4%, current ratio 6.64x
- Beta 0.23, current ratio 6.64x
- Beta 0.23 vs ISRG's 1.00
ISRG is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 5.5% 10Y total return vs PEN's 5.0%
- 20.5% revenue growth vs MDT's 3.6%
- 28.2% margin vs ZBH's 9.1%
SYK is the clearest fit if your priority is valuation efficiency.
- PEG 1.28 vs MDT's 35.17
MDT ranks third and is worth considering specifically for income & stability.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- 3.7% yield, 36-year raise streak, vs SYK's 1.2%, (2 stocks pay no dividend)
- 175.8% ROA vs ZBH's 3.3%, ROIC 6.0% vs 5.4%
ZBH is the clearest fit if your priority is value.
- Lower P/E (9.7x vs 13.8x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs MDT's 3.6% | |
| Value | Lower P/E (9.7x vs 13.8x) | |
| Quality / Margins | 28.2% margin vs ZBH's 9.1% | |
| Stability / Safety | Beta 0.23 vs ISRG's 1.00 | |
| Dividends | 3.7% yield, 36-year raise streak, vs SYK's 1.2%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +11.6% vs SYK's -24.5% | |
| Efficiency (ROA) | 175.8% ROA vs ZBH's 3.3%, ROIC 6.0% vs 5.4% |
PEN vs ISRG vs SYK vs MDT vs ZBH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PEN vs ISRG vs SYK vs MDT vs ZBH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
ZBH leads 1 • PEN leads 1 • MDT leads 1 • SYK leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 24.4x PEN's $1.5B. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ZBH's 9.1%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $10.6B | $25.1B | $35.5B | $8.4B |
| EBITDAEarnings before interest/tax | $200M | $3.8B | $6.3B | $9.4B | $2.3B |
| Net IncomeAfter-tax profit | $171M | $3.0B | $3.2B | $4.6B | $761M |
| Free Cash FlowCash after capex | $213M | $2.8B | $4.3B | $5.4B | $1.8B |
| Gross MarginGross profit ÷ Revenue | +67.4% | +66.3% | +63.5% | +61.9% | +70.0% |
| Operating MarginEBIT ÷ Revenue | +12.9% | +30.5% | +22.4% | +17.9% | +15.6% |
| Net MarginNet income ÷ Revenue | +11.8% | +28.2% | +12.9% | +13.0% | +9.1% |
| FCF MarginFCF ÷ Revenue | +14.6% | +26.8% | +17.1% | +15.2% | +21.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.6% | +23.0% | +11.4% | +8.8% | +9.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -18.0% | +18.8% | +56.0% | -11.9% | +34.1% |
Valuation Metrics
ZBH leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 70% valuation discount to PEN's 71.3x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs MDT's 35.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12.7B | $159.8B | $109.3B | $97.6B | $16.1B |
| Enterprise ValueMkt cap + debt − cash | $12.7B | $156.8B | $120.2B | $123.9B | $23.0B |
| Trailing P/EPrice ÷ TTM EPS | 71.29x | 57.19x | 33.98x | 21.09x | 23.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 65.80x | 43.35x | 19.06x | 13.80x | 9.71x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.63x | 2.29x | 35.17x | — |
| EV / EBITDAEnterprise value multiple | 61.47x | 43.28x | 19.76x | 14.06x | 9.38x |
| Price / SalesMarket cap ÷ Revenue | 9.03x | 15.88x | 4.35x | 2.91x | 1.96x |
| Price / BookPrice ÷ Book value/share | 8.87x | 9.10x | 4.87x | 2.04x | 1.29x |
| Price / FCFMarket cap ÷ FCF | 72.45x | 64.18x | 25.53x | 18.83x | 10.95x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $6 for ZBH. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), PEN scores 7/9 vs ZBH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +12.3% | +16.9% | +15.0% | +9.4% | +5.8% |
| ROA (TTM)Return on assets | +9.6% | +14.8% | +6.9% | +175.8% | +3.3% |
| ROICReturn on invested capital | +11.3% | +15.0% | +11.4% | +6.0% | +5.4% |
| ROCEReturn on capital employed | +12.5% | +16.5% | +13.0% | +7.5% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.15x | 0.02x | 0.66x | 0.59x | 0.59x |
| Net DebtTotal debt minus cash | $33M | -$3.1B | $10.8B | $26.3B | $6.9B |
| Cash & Equiv.Liquid assets | $187M | $3.4B | $4.0B | $2.2B | $592M |
| Total DebtShort + long-term debt | $220M | $303M | $14.9B | $28.5B | $7.5B |
| Interest CoverageEBIT ÷ Interest expense | 304.65x | — | 6.72x | 9.08x | 4.08x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $5,222 for ZBH. Over the past 12 months, PEN leads with a +11.6% total return vs SYK's -24.5%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.1% vs ZBH's -14.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +4.1% | -19.9% | -17.8% | -20.0% | -8.3% |
| 1-Year ReturnPast 12 months | +11.6% | -16.4% | -24.5% | -5.5% | -12.4% |
| 3-Year ReturnCumulative with dividends | +3.7% | +48.5% | +2.4% | -6.3% | -38.0% |
| 5-Year ReturnCumulative with dividends | +22.3% | +61.7% | +17.5% | -29.2% | -47.8% |
| 10-Year ReturnCumulative with dividends | +501.4% | +549.2% | +179.2% | +24.3% | -18.8% |
| CAGR (3Y)Annualised 3-year return | +1.2% | +14.1% | +0.8% | -2.1% | -14.7% |
Risk & Volatility
PEN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PEN is the less volatile stock with a 0.23 beta — it tends to amplify market swings less than ISRG's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PEN currently trades 88.9% from its 52-week high vs SYK's 70.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.23x | 1.00x | 0.52x | 0.42x | 0.60x |
| 52-Week HighHighest price in past year | $362.41 | $603.88 | $404.87 | $106.33 | $108.29 |
| 52-Week LowLowest price in past year | $221.26 | $427.84 | $284.97 | $75.91 | $79.83 |
| % of 52W HighCurrent price vs 52-week peak | +88.9% | +74.5% | +70.5% | +71.6% | +76.0% |
| RSI (14)Momentum oscillator 0–100 | 38.1 | 43.6 | 26.6 | 29.2 | 36.2 |
| Avg Volume (50D)Average daily shares traded | 533K | 1.8M | 2.1M | 7.9M | 2.2M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PEN as "Hold", ISRG as "Buy", SYK as "Buy", MDT as "Buy", ZBH as "Hold". Consensus price targets imply 43.8% upside for MDT (target: $110) vs 14.8% for PEN (target: $370). For income investors, MDT offers the higher dividend yield at 3.65% vs ZBH's 1.16%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $369.83 | $622.60 | $389.62 | $109.50 | $96.33 |
| # AnalystsCovering analysts | 22 | 55 | 50 | 49 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.2% | +3.7% | +1.2% |
| Dividend StreakConsecutive years of raises | — | — | 34 | 36 | 0 |
| Dividend / ShareAnnual DPS | — | — | $3.36 | $2.78 | $0.96 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | +3.3% | +3.0% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZBH leads in 1 (Valuation Metrics).
PEN vs ISRG vs SYK vs MDT vs ZBH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PEN or ISRG or SYK or MDT or ZBH a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PEN or ISRG or SYK or MDT or ZBH?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Penumbra, Inc. at 71. 3x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Medtronic plc's 35. 17x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — PEN or ISRG or SYK or MDT or ZBH?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +61. 7%, compared to -47. 8% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus ZBH's -18. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PEN or ISRG or SYK or MDT or ZBH?
By beta (market sensitivity over 5 years), Penumbra, Inc.
(PEN) is the lower-risk stock at 0. 23β versus Intuitive Surgical, Inc. 's 1. 00β — meaning ISRG is approximately 336% more volatile than PEN relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PEN or ISRG or SYK or MDT or ZBH?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Penumbra, Inc. grew EPS 1156% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, PEN leads at 18. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PEN or ISRG or SYK or MDT or ZBH?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 8. 6% for Zimmer Biomet Holdings, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 13. 5% for PEN. At the gross margin level — before operating expenses — PEN leads at 67. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PEN or ISRG or SYK or MDT or ZBH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Medtronic plc's 35. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 7x forward P/E versus 65. 8x for Penumbra, Inc. — 56. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 43. 8% to $109. 50.
08Which pays a better dividend — PEN or ISRG or SYK or MDT or ZBH?
In this comparison, MDT (3.
7% yield), SYK (1. 2% yield), ZBH (1. 2% yield) pay a dividend. PEN, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is PEN or ISRG or SYK or MDT or ZBH better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, ISRG: +549. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PEN and ISRG and SYK and MDT and ZBH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PEN is a mid-cap high-growth stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ZBH is a mid-cap quality compounder stock. SYK, MDT, ZBH pay a dividend while PEN, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.